| Dr Neil Richard Stockmaster, MD | |
|
1 Jarrett White Rd, Tripler Army Medical Center, HI 96859-5001 | |
| (808) 433-2592 | |
| Not Available |
| Full Name | Dr Neil Richard Stockmaster |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 24 Years |
| Location | 1 Jarrett White Rd, Tripler Army Medical Center, Hawaii |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417914532 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 25MA08563800 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Straub Clinic And Hospital | Honolulu, HI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Straub Clinic And Hospital | 6305759754 | 404 |
News Archive
Onconova Therapeutics, Inc. today announced positive human safety, tolerability, and pharmacokinetic data from three clinical trials of Ex-RAD (recilisib sodium, ON 01210.Na), a novel radioprotectant being developed as a medical countermeasure for the treatment of acute radiation syndrome (ARS).
A provision of U.S. law that bans HIV-positive foreigners from entering the country is harming testing efforts and excluding eligible candidates for citizenship, according to members of a panel held by the Global Health Council on Nov. 15, CQ HealthBeat reports.
Cognition Therapeutics Inc., a drug discovery company developing novel, small molecule disease-modifying treatments for Alzheimer's, has closed on a $2.5 million Series A1 financing it will use to bring one or more of its compounds to Investigational New Drug (IND) candidate status. The round was led by Golden Seeds, one of the nation's largest angel investing groups, and was syndicated with Tech Coast Angels.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 8 days ago
| Entity Name | Straub Clinic & Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457306508 PECOS PAC ID: 6305759754 Enrollment ID: O20031111000417 |
News Archive
Onconova Therapeutics, Inc. today announced positive human safety, tolerability, and pharmacokinetic data from three clinical trials of Ex-RAD (recilisib sodium, ON 01210.Na), a novel radioprotectant being developed as a medical countermeasure for the treatment of acute radiation syndrome (ARS).
A provision of U.S. law that bans HIV-positive foreigners from entering the country is harming testing efforts and excluding eligible candidates for citizenship, according to members of a panel held by the Global Health Council on Nov. 15, CQ HealthBeat reports.
Cognition Therapeutics Inc., a drug discovery company developing novel, small molecule disease-modifying treatments for Alzheimer's, has closed on a $2.5 million Series A1 financing it will use to bring one or more of its compounds to Investigational New Drug (IND) candidate status. The round was led by Golden Seeds, one of the nation's largest angel investing groups, and was syndicated with Tech Coast Angels.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 8 days ago
| Entity Name | Maui Health System A Kaiser Foundation Hospitals Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013379460 PECOS PAC ID: 9830476159 Enrollment ID: O20170725002612 |
News Archive
Onconova Therapeutics, Inc. today announced positive human safety, tolerability, and pharmacokinetic data from three clinical trials of Ex-RAD (recilisib sodium, ON 01210.Na), a novel radioprotectant being developed as a medical countermeasure for the treatment of acute radiation syndrome (ARS).
A provision of U.S. law that bans HIV-positive foreigners from entering the country is harming testing efforts and excluding eligible candidates for citizenship, according to members of a panel held by the Global Health Council on Nov. 15, CQ HealthBeat reports.
Cognition Therapeutics Inc., a drug discovery company developing novel, small molecule disease-modifying treatments for Alzheimer's, has closed on a $2.5 million Series A1 financing it will use to bring one or more of its compounds to Investigational New Drug (IND) candidate status. The round was led by Golden Seeds, one of the nation's largest angel investing groups, and was syndicated with Tech Coast Angels.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Neil Richard Stockmaster, MD 91-1110 Kaiko St, Ewa Beach, HI 96706-6033 Ph: (808) 269-7493 | Dr Neil Richard Stockmaster, MD 1 Jarrett White Rd, Tripler Army Medical Center, HI 96859-5001 Ph: (808) 433-2592 |
News Archive
Onconova Therapeutics, Inc. today announced positive human safety, tolerability, and pharmacokinetic data from three clinical trials of Ex-RAD (recilisib sodium, ON 01210.Na), a novel radioprotectant being developed as a medical countermeasure for the treatment of acute radiation syndrome (ARS).
A provision of U.S. law that bans HIV-positive foreigners from entering the country is harming testing efforts and excluding eligible candidates for citizenship, according to members of a panel held by the Global Health Council on Nov. 15, CQ HealthBeat reports.
Cognition Therapeutics Inc., a drug discovery company developing novel, small molecule disease-modifying treatments for Alzheimer's, has closed on a $2.5 million Series A1 financing it will use to bring one or more of its compounds to Investigational New Drug (IND) candidate status. The round was led by Golden Seeds, one of the nation's largest angel investing groups, and was syndicated with Tech Coast Angels.
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
› Verified 8 days ago
Dr. John Jacob Verghese, M.D Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1 Jarrett White Rd, Department Of Surgery, Tripler Army Medical Center, HI 96859 Phone: 808-433-3478 |